Top Stories
-
3 years ago
Vienna is establishing a service point in the city hall
thestoriest.com
-
3 years ago
RTK-Präsident Thomas Ziegler und gesamter Vorstand wiedergewählt
tourismuspresse.at
-
3 years ago
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
biospace.com
-
3 years ago
Austria sees sharp rise in acts of antisemitism
euractiv.com
-
3 years ago
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
newser.com
-
3 years ago
Exit poll shows Swiss right-wing party bouncing back in parliamentary election as Greens lose ground
sfgate.com
-
3 years ago
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
globenewswire.com
-
3 years ago
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
finance.yahoo.com
-
3 years ago
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
wreg.com